Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
Express Scripts
Moodys
McKinsey

Last Updated: August 14, 2022

Investigational Drug Information for Mipsagargin


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Mipsagargin?

Mipsagargin is an investigational drug.

There have been 6 clinical trials for Mipsagargin. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2014.

The most common disease conditions in clinical trials are Glioblastoma, Carcinoma, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are GenSpera, Inc., John Wayne Cancer Institute, and [disabled in preview].

There are three US patents protecting this investigational drug and nine international patents.

Recent Clinical Trials for Mipsagargin
TitleSponsorPhase
Efficacy and Safety of G-202 in PSMA-Positive GlioblastomaJohn Wayne Cancer InstitutePhase 2
Efficacy and Safety of G-202 in PSMA-Positive GlioblastomaGenSpera, Inc.Phase 2
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMAGenSpera, Inc.Phase 2

See all Mipsagargin clinical trials

Clinical Trial Summary for Mipsagargin

Top disease conditions for Mipsagargin
Top clinical trial sponsors for Mipsagargin

See all Mipsagargin clinical trials

US Patents for Mipsagargin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mipsagargin See Plans and Pricing Methods of treating glioblastoma multiforme using ibudilast MediciNova, Inc. (La Jolla, CA) See Plans and Pricing
Mipsagargin See Plans and Pricing Methods of treating disorders with glycosylation defective proteins CASE WESTERN RESERVE UNIVERSITY (Cleveland, OH) See Plans and Pricing
Mipsagargin See Plans and Pricing Methods and dosing regimens using ibudilast and a second agent for cancer therapy MediciNova, Inc. (La Jolla, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Mipsagargin

Drugname Country Document Number Estimated Expiration Related US Patent
Mipsagargin European Patent Office EP3558301 2036-12-22 See Plans and Pricing
Mipsagargin Japan JP2020504721 2036-12-22 See Plans and Pricing
Mipsagargin World Intellectual Property Organization (WIPO) WO2018119262 2036-12-22 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.